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Background: Metabolic syndrome, a cluster of classical cardiovascular risk factors, including hypertension, obesity,
glucose intolerance, and dyslipidemia is highly prevalent in patients with rheumatoid arthritis (RA). The aim of the
study was to assess the frequency of metabolic syndrome (MS) in RA patients, and to evaluate the relationships
between metabolic syndrome and RA.
Methods: The study was conducted on 120 RA patients according to the 1987 revised American College of
Rheumatology classification criteria, and 100 age and sex matched apparently healthy controls. The frequency of
metabolic syndrome was assessed using six Metabolic Syndrome definitions (Joint Consensus 2009, National
Cholesterol Education Programme 2004 and 2001, International Diabetes Federation, World Health Organisation and
European Group for Study of Insulin Resistance). Logistic regression was used to identify independent predictors of
metabolic Syndrome.
Results: The frequency of metabolic syndrome varied from 18 to 48.6% in RA according to the definition used and
was significantly higher than controls (for all definitions p<0.05). In multivariate analysis, higher ESR was
independently associated with the presence of Met S (OR =1.36; CI: 1.18–2.12; p = 0.03). Glucocorticoid use, but not
other disease modifying anti-rheumatic drugs (DMARDs), values remained significant independent predictors of the
presence of metabolic syndrome in RA patients (OR = 1.45; CI: 1.12–2.14; p = 0.04).
Conclusions: In summary, the frequency of metabolic syndrome in RA varies according to the definition used and
was significantly higher compared to controls (for all definitions p<0.05). Higher systemic inflammatory marker, and
glucocorticoids use were independent predictors associated with the presence of metabolic syndrome in patients
with RA. These findings suggest that physicians should screen for metabolic syndrome in patients with RA to
control its components and therefore reduce the risk of cardiovascular disease in these patients.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease associated with increased disability, morbidity and
mortality [1,2]. CVD has turned out to be one of the
most important causes of death in RA patients [3].
Therefore, the European League Against Rheumatism
(EULAR) guidelines recommend that cardiovascular risk
screening and management to be urgently done in pa-
tients with RA [4].
Metabolic syndrome and Inflammation are intimately
linked. Inflammatory biomarkers are frequently elevated* Correspondence: rostomsamira2003@yahoo.fr
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reproduction in any medium, provided the orin people with Met S and conversely, the prevalence of
Met S is higher in patients with chronic inflammatory
rheumatic diseases [5].
Metabolic syndrome main components are dyslipidemia
(elevated triglycerides and apolipoprotein B (apoB)-
containing lipoproteins, and low high-density lipoproteins
(HDL)), elevation of arterial blood pressure (BP) and
dysregulated glucose homeostasis, while abdominal
obesity and/or insulin resistance (IR) have gained
increasing attention as the core manifestations of the
syndrome [6]. Recently, other abnormalities such as
prothrombotic states, non-alcoholic fatty liver disease and
sleep apnea have been added to the entity of the
syndrome, making its definition even more complex [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metabolic syndrome, there are still no clearly defined
diagnostic criteria. Several studies have examined the
prevalence of Met S in RA subjects and whether it is
increased compared to subjects without RA, but the
results have been inconsistent, maybe due to the differ-
ences in metabolic syndrome definitions and in study
populations [7,8]. The frequency of metabolic syndrome
in RA patients is influenced not only by traditional factors
such as race, age, and dietary habits, but also by disease-
specific factors.
Morocco is one of the countries of North Africa with un-
met need of sustainable healthcare delivery systems. North
Africa is a region with challenging political, climatic and
geographical conditions. Data from small studies in the re-
gion showed that RA is frequently diagnosed late and many
patients present with active disease and severe disability.
Despite this, only a small proportion of patients receive
DMARDs particularly biologic DMARDS, and the scarcity
of medical and social resources is a barrier to appropriate
treatment in many countries [9-14]. Morocco had also par-
ticipated in two international studies: QUEST RA study
[15], which is a successful example of quantitative clinical
measuring of RA as part of routine clinical care in a large
number of centers across more than 30 countries including
countries from Europe (France, Germany, Netherlands....),
USA, Argentina, Brazil, Morocco, and United Arab
Emirates. This study has suggested high disease activity in
our country. The second study is COMORA study:
comorbidities in RA (data not yet published), these two
studies suggest a high disease activity in our country (300
patients from 10 centers of the country), the use of high-
dose of corticoids, and a more frequent association with
hyeprtension pressure, dyslipidemia, overweight and less fre-
quent exposure to tobacco and alcohol. Solomon A et al.
[16] have assessed the risk factor profiles for atherosclerotic
cardiovascular disease in black and other Africans with
established rheumatoid arthritis and found that proportions
of individual metabolic syndrome components differed be-
tween black and other patients but their total numbers of
metabolic risk factors and metabolic syndrome frequencies
were similar. From these data from cross-sectional studies
in Africa, we can assume that the activity profile and Sever-
ity of RA in Africa is quite different fromWestern countries.
Furthermore, metabolic syndrome and activity are intimately
linked. Hence, we aimed to assess the frequency of meta-
bolic syndrome and its components and evaluate the sup-




Our study included 120 consecutive patients with
RA fulfilling the 1987 revised American College ofRheumatology classification criteria [17] over a period
of 13 months (between May 2010 and June 2011) at the
department of rheumatology of El Ayachi tertiary uni-
versity hospital of Rabat-Sale from outpatient and in-
patient services.
Patients with other inflammatory diseases, malignan-
cies, diseases of the central nervous system, chronic kid-
ney disease, chronic liver disease besides RA, were
excluded from the study.
Healthy controls
One hundred age-, sex-, and race-matched apparently
healthy volunteers’ women and men from urban and
rural residences of the Rabat-Salé province in Morocco
served as the control group in the present study. Healthy
subjects were represented by families of patients (n=36),
or families of medical or paramedical staff of the hospital
(n=64).
Informed consent was obtained from all subjects. The
study was approved by the Research and Ethical Review
Board of the Avicenne University Hospital, Rabat, Morocco.
Methods
Clinical assessment
Demographic characteristics, disease-specific variables (dis-
ease duration, duration of morning stiffness, the number of
nocturnal awakenings, tender and swollen joint count…)
drug use (all anti-rheumatic drugs, glucocorticoid use, car-
diovascular drugs and analgesics among others), comorbid
conditions, and family history of rheumatic and cardiovascu-
lar diseases were documented for each patient.
Disease activity and function
The Disease Activity Score including 28 joints (DAS28)
was used, evaluating the number of swollen joints, num-
ber of tender joints, the patients’ global assessment of
health measured on a visual analogic scale (VAS, range
0-100 mm), and erythrocyte sedimentation rate (ESR). A
score of DAS28 between 2.6-3.2 indicates low disease ac-
tivity, > 3.2- ≤ 5.1 moderate and > 5.1 high disease activ-
ity [18]. The patients also completed the validated
Arabic translation of the Health Assessment Question-
naire (HAQ) [19], which served to evaluate functional
disability; the HAQ score can range from 0 (no disabil-
ity) to 3 (greatest possible disability). Pain and general
health were measured by a visual analogic scale (VAS).
Body composition
Body mass index (BMI) was calculated from weight/
height2 (kg/m2). BMI values < 18.5 kg/m2 are considered
underweight, between 18.5-24.9 as normal, 25-29.9 as over-
weight and values greater than 30 indicate obesity
[20]. Waist circumference (WC) was measured to the
nearest 0.5 cm midway between the iliac crest and
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Diabetes Federation (IDF) a waist circumference value
less than 80 cm indicate low risk of type 2 diabetes, co-
ronary heart disease or hypertension [21]. BP was mea-
sured by a mercury sphygmomanometer in the sitting
position after five minutes of rest. Hypertension was de-
fined by blood pressure ≥ 130 mmHg for systolic pres-
sure or ≥ 85 mmHg diastolic pressure or current
treatment for hypertension.Biochemical measures
Biological tests were performed from venous blood
samples obtained the morning after an overnight fast.
Plasma fasting glucose (FG) levels were measured using
the glucose oxydase method. C-reactive protein (CRP),
ESR, total cholesterol, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) were determined by
standard laboratory methods. Concentrations of total choles-
terol > 5.0 mmol/L, LDL ≥ 3.0 mmol/L, HDL < 1.3 mmol/L
were considered pathologic [22]. A renal function assessment
was performed by estimation of glome-rular filtration rate
according to the Modification of Diet in Renal Disease
(MDRD) equation.Table 1 A summary of the definitions of the metabolic syndro










WC ≥ 94 cm men,








≥130/≥85 or treatment ≥ 130/85
Dyslipidaemia:
HDL-C ≥ 40 mg/dL





≥ 40 mg/dL (1.03 mol/L)



















(5.6 mmol/L) or T2D




* cut-off values differ according to ethnic origin , for Mediterranean and sub Sahari
IDF definition;
BMI = body mass index; JC= Joint Consensus; DM = diabetes mellitus; EGIR = Europ
lipoproteincholesterol; IDF = International Diabetes Federation; IGT = impaired gluc
Education Programme Adult Treatment Panel; T2 D, type II diabetes mellitus; WC =
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with the presence of at least two other components from a list of five components.Metabolic syndrome
Metabolic syndrome is a cluster of classical cardiovascular
risk factors (obesity, glucose intolerance, dyslipidaemia, and
hypertension). It is thought to be associated with cardiovas-
cular risk beyond the sum of its individual components [23],
although this has recently been questioned.Currently used criteria to define Met S
Despite the great interest in this subject, no consensus has
been reached yet regarding the definition of Met S. Several
groups have attempted to establish diagnostic criteria; the
most widely used have been provided by many international
organizations and expert groups, such as the World Health
Organization (WHO) [24], the European Group for the
study of Insulin Resistance (EGIR) [25], the National Choles-
terol Education Program Adult Treatment Panel III (NCEP:
ATPIII) [26], the International Diabetes Federation (IDF)
[27] and the Joint Consensus (JC) [28]. They have attempted
to incorporate all the different parameters used to define
MetS (Table 1). In this study, the prevalence of Met S was
assessed according to all existing definitions (JC, NCEP
2004, NCEP 2001, WHO, IDF, EGIR (Table 1) in order to
establish the range of discrepancy between them. For furtherme [20-27]
P III NCEP ATP III (2001) EGIR 1999 WHO 1998
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on the presence of diabetes, glucose intolerance or insulin resistance together
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NCEP 2004 definition is presented, as it is the most widely
used definition reported in the literature, thus allowing com-
parisons with other studies to be drawn [27].Statistical analysis
Statistical analysis was performed with SPSS 13, 0 statis-
tical software packages. The statistical analysis of patient
questionnaire data involved computation of means, me-
dians, standard deviations, ranges for quantitative vari-
ables; and numbers and percentages for qualitative
variables. Sample t test were used to compare quantitative
data and the chi-square test for qualitative data. Multivari-
ate logistic regression models were constructed and odds
ratios (OR) and 95% confidence intervals (CI) were calcu-
lated to investigate the independence of the predictors of
individual RA-related characteristics and Met S.Results
Description of the RA patients
A summary of the socio-demographic and clinical char-
acteristics of the patients is presented in Table 2. The
mean age of the 120 patients examined was 49±12 years.
Most of the patients were female 110 (91.7%). Patients
had mean disease duration of 7.8 years, and had moder-
ate disease activity (the mean DAS 28 score was
5±1.4), the mean HAQ score was 1.4±0.7. The majority
of patients with RA were currently treated with disease-
modifying anti-rheumatic drugs (DMARDs) (96%). The
breakdown of DMARD usage was: 117 (96%) patients
were taking methotrexate, 68 (56%) sulphasalazine, 21
(18%) hydroxychloroquine and glucocorticoids (96%)
with mean daily dose of 7.3±3 mg/j.Table 2 Demographic and anthropometric characteristics of p
Variables RA patients
(N=120)
Age (years)1 49 ± 12
female Sex2 110 (91.7 )
Menopause2 63(51.1)
Body mass index3 28.1 (22.4 to 30.8)
Waist circumference3 91.4 (83.8 to 93.4)
Systolic blood pressure (mmHg)3 132.3 (126.1 to 130.5)
Diastolic blood pressure (mmHg)3 79.1 (77.9 to 80.3)
Total cholesterol, (mmol/l)3 5.4 (5.2 to 5.6)
HDL-cholesterol, (mmol/l)3 1.32 (1.25 to 1.37)
LDL-cholesterol, (mmol/l)3 3.3 (2.8 to 3.4)
Triglycerides, (mmol/l)3 2.09 (2.06 to 2.14)
Fasting plasma glucoce, (mmol/l)3 5.4 (5.3 to 5.5)
1: mean and standard deviation, 2: number and percentage, 3: median and quartileFrequency of metabolic syndrome in the study
population according to the definition used and
comparison with healthy controls
There was a great diversity in the reported prevalence
rates according to the definition used (Table 3). The
prevalence ranged from 18% to 48.6%. The most updated
Joint Consensus 2009 criteria and most commonly used
NCEP 2004 reporting a rate of 32.4%. For all definitions,
metabolic syndrome had significantly lower frequency in
control groups than in patients with RA (p < 0.05).Associations of Metabolic syndrome in patients with RA
Characteristics of patients with RA who had and who did
not have Met S are presented in Table 4. The Results
presented were only for the NCEP 2004 criteria, but were
very similar when we used other criteria, despite the dif-
ference in prevalence. In univariate analysis, patients in
the groups with Met S were older (p = 0.03) and had a
higher ESR (P = 0.02) and higher HAQ score (p= 0.03),
than those without Met S. No significant differences were
seen between the two groups according to disease activity
and disease duration. TG, Fasting plasma glucoce and sys-
tolic blood pressure were significantly higher in the group
with Met S (P= 0.04, P<0.001, P =0.03 respectively) com-
pared with those who did not have the MetS. Methotrex-
ate, Sulphasalazine, hydroxychloroquine use was not
significantly associated with the presence of the Met S.
Furthermore glucocorticoid use was associated with the
presence of the Met S (P=0.003). The independence of
each of these associations was tested, in a multivariate lo-
gistic regression model, an association between metabolic
syndrome, ESR and glucocorticoids use persisted and
remained a significant independent predictor of the pres-




48.5 ± 13 0.78
90 (90) 0.88
61(61) 0.97
24.5 (22.4 to 26.4) 0.23
80.4 (77.2 to 82.8) 0.001
117.6 (115.5 to 119.7) 0.01
71.4 (70.3 to 74.5) 0.12
5.2 (5.1 to 5.3) 0.32
1.64 (1.60 to 1.70) 0.02
2.4 (2.3 to 2.68) 0.04
1.97 (1.94 to 1.99) 0.23
5.2 (5.1 to 5.4) 0.34
s.
Table 3 Prevalence of metabolic syndrome according to definition used
Definitions JC 2009 IDF 2005 NCEP 2004 NCEP 2001 EGIR 1999 WHO 1998
Controls 18 23 18 16 12 14
Rheumatoid arthritis 32.3* 48.6* 32.4* 24.6* 18* 20*
* For all definitions p<0.05.
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This case-control study suggested that RA is associated
with increased frequency of metabolic syndrome com-
pared to control groups, but its frequency depends on the
definition used. Higher systemic inflammatory markers
(ESR) and glucocorticoid use were independent predictors
associated with the presence of metabolic syndrome in
patients with RA.
The metabolic syndrome describes a constellation of
major risk factors for cardiovascular diseases (CVDs)
such as atherogenic dyslipidemia, obesity, hypertension
and diabetes. These associated risk factors have been
previously called syndrome X2 or the insulin resistance
syndrome [29].
The frequency of metabolic syndrome has varied mark-
edly between different studies [30], most likely because of
the lack of accepted criteria for the definition of metabolic
syndrome. Recently, Karvounaris et al found a frequency
of metabolic syndrome (defined according to the NCEP
ATP III criteria) in RA patients (40%), comparable with
their control population [29]. In South Asia, Dodani
and al found that the frequency of metabolic syndrome
was 13.3% and 40%, respectively, according to WHO
and NCEP ATP III criteria [31]. Another study showed
that metabolic syndrome was significantly more prevalentTable 4 Main characteristics of patients with rheumatoid arth
absence of metabolic syndrome
Characteristics Total (n=120)
Mean Age (years)1 49± 12
Female Sex n (%)2 110 (91.7 )
Menopause n(%)2 63(51.1)
RF positive n (%)2 93(76)
ACPA positive n (%)2 104(85)
Disease duration (yrs)1 7.8 ± 5.3
CRP (mg/L)1 17(1à 112)
ESR (mm 1erhour)1 33± 23
DAS281 5 ± 1.4
Global pain (VAS : 0-100 mm)1 54 ± 21
HAQ1 1.4± 0.7
Methotrexate n (%)2 117(96)
glucocorticoids mean daily dose (mg/j)1 7.3±3.05
1: Mean ± standard deviation, 2: number (percentage). ACPA = anti-cyclic citrullinate
Activity Score; ESR = erythrocyte sedimentation rate; HAQ = Health Assessment Qu
RA = rheumatoid arthritis; RF = rheumatoid facto; BMI= Body mass index; VAS= visuin American patients with long-standing RA (42% –
WHO and NCEP/ATPIII criteria) as well as in early
RA patients (31% and 30% – WHO and NCEPIII criteria
respectively) than in controls (11% and 22% – WHO
and NCEP/ATPIII criteria, respectively) [32]. Allowing
comparison of our results with those of other studies in
RA and other conditions, In the literature, the frequency
of metabolic syndrome varied considerably, even using
the same criteria; for example, using the NCEP 2001,
the frequency ranged from 17% in Mexican [33], 19%
in South African [7], 19.9% in Dutch [34], 38.3% in English
[35], to 41.5% in Swedish [36], 42% in American [32],
and 44% in Greek [29] patients with RA and 24.6%
in our study. Such diversity can be explained by
differences in the baseline characteristics and disease
characteristics [37].
The factors found in this study to be associated
independently with the metabolic syndrome in RA, irre-
spective of the definition used, included higher systemic
inflammatory markers, and glucocorticoid usage. In our
study, we didn’t find an association between older age
and metabolic syndrome contrary to others studies
[15,16]. The association with older age is not surprising,
because in the general population, metabolic syndrome
has been shown to affect primarily older subjects, as aritis included in this study according to the presence or
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17±21 19±19 0.59
24± 23 37± 24 0.04





d peptide; BP = blood pressure; CRP = C-reactive protein; DAS =Disease
estionnaire; HDL =high-density lipoprotein; MetS = metabolic syndrome;
al analogic scale.
Table 5 Odds ratios for having the metabolic syndrome in patients with RA
Univariate analysis Multivariate analysis
OR IC95% P OR 95% CI P
Age (years) 1.33 1.19-2.35 0.03 1.13 1.18-1.76 0.07
Disease duration (years) 1.03 0.96-1.11 0.32
DAS28 1.16 0.87-1.55 0.28
HAQ 1.45 1.12-2.5 0.03 1. 13 0.90-2.13 0.16
MTX 0.01 0.03-1.7 0.76
Glucocorticoids use 1.93 1.34-3.92 0.003 1.45 1.12-2.14 0.04
CRP 1.01 0.88-1.02 0.60
ESR 2.21 1.99-2.62 0.002 1.36 1.18-2.12 0.03
DAS =Disease Activity Score; ESR = erythrocyte sedimentation rate; HAQ = Health Assessment Questionnaire; CRP = C-reactive protein; MTX =methotrexate. The
factors included in the multivariate analysis were age, HAQ, glucorticoids use, and ESR.
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components [38]. The association between higher ESR
and the presence of metabolic syndrome in patients with
RA in our study was also previously reported [38]. These
findings further support the role of chronic inflamma-
tion in insulin resistance development [39,40]. However,
ESR can be affected by a number of comorbid condi-
tions (renal disease) as well as age. Furthermore, meta-
bolic syndrome is an inflammatory condition, and thus
ESR may be elevated to some degree by the presence of
metabolic syndrome. Moreover, the cross-sectional de-
sign of our study limit the ability to describe causal rela-
tionships to the associations detected.
Another finding from this study was the association be-
tween glucocorticoids use and the presence of metabolic
syndrome. This relationship may be explained by the effects
of glucocorticoids on different components of the lipid pro-
file. To the contrary, the study among Mediterranean RA
patients found that metabolic syndrome in RA is independ-
ent of gender and body mass index (BMI) [29,32]. Current
corticosteroid use does not increase the risk of metabolic
syndrome [35,41] while it may even reduce its prevalence
[36]. On the other hand, the risk of having moderate to se-
vere RA is higher in patients with metabolic syndrome than
in those without the syndrome [29]. Furthermore, another
study showed that the use of glucocorticoids is not associ-
ated with the presence of metabolic syndrome [41]. Dessein
and coworkers found that corticosteroid use was not associ-
ated with dyslipidemia in RA patients [42] but was associ-
ated with insulin resistance. Therefore, the lipoprotein
effects of glucocorticoids are unlikely to be the sole cause (if
any) of the impact of these drugs on cardiovascular risk. In-
deed, the analysis of lipid levels in the COBRA (“Combin-
ation therapy in rheumatoid arthritis”) study found that
combination therapy with glucocorticoids, methotrexate,
and sulfasalazine was associated with a more rapid and fa-
vorable impact on the atherogenic index (total/HDL choles-
terol ratio) in RA [42]. In the literature, Glucocorticoid use
is associated with adverse lipid profiles in the generalpopulation, and its long-term use is a risk factor for CVD
[43]. However, the relationship between glucocorticoid use
and cardiovascular risk in patients with RA is complicated
by the fact that these drugs tend to be used more often in
patients with severe or intractable disease; therefore, it is dif-
ficult to determine whether the disease or the treatment in-
crease the risk [44].
The limitations of the current study should be addressed.
The cross-sectional design and small size of our study limit
the ability to describe causal relationships to the associations
detected. Furthermore; the small sample size of this study,
and recruitment from a single center, which is a tertiary care
center with recruitment of the most active and severe dis-
ease expose to bias selection and the risk of surestmation of
the real frequency of metabolic syndrome. The international
COMORA study (comorbidities in RA); in which Morocco
has participated with 300 patients across 10 centers in the
country (private and public structures) will be interesting,
it can given the frequency of metabolic syndrome and its
components and compared these data through countries.
Moreover, the Moroccan ESPOIR study (Etude et Suivi des
POlyarthrites rhumatoïdes et arthrites Indifférenciées Ré-
centes), a prospective multicenter cohort study of 10 years of
follow-up will provide some information on the epidemio-
logical profile of the RA in Morocco. Further prospective
studies should prove valuable in determining these causal
relationships.
Conclusion
In summary, this study shows that rheum arthritis has
been associated with increased prevalence of metabolic
syndrome compared to control groups. A higher sys-
temic inflammatory marker and glucocorticoid use were
independent predictors associated with the presence of
metabolic syndrome in patients with RA. These findings
suggest that clinicians should screen for metabolic syn-
drome in patients with RA to control its components
and, therefore, reduce the risk of cardiovascular disease
in these patients
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